- Home
- GLPG vs TRN Comparison
GLPG vs TRN Comparison
Compare GLPG & TRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- TRN
- Stock Information
- Founded
- GLPG 1999
- TRN 1933
- Country
- GLPG Belgium
- TRN United States
- Employees
- GLPG N/A
- TRN N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- TRN Railroads
- Sector
- GLPG Health Care
- TRN Industrials
- Exchange
- GLPG Nasdaq
- TRN Nasdaq
- Market Cap
- GLPG 2.1B
- TRN 2.2B
- IPO Year
- GLPG 2005
- TRN N/A
- Fundamental
- Price
- GLPG $34.45
- TRN $27.84
- Analyst Decision
- GLPG Sell
- TRN Hold
- Analyst Count
- GLPG 3
- TRN 1
- Target Price
- GLPG $26.00
- TRN $24.00
- AVG Volume (30 Days)
- GLPG 203.5K
- TRN 490.5K
- Earning Date
- GLPG 10-29-2025
- TRN 10-30-2025
- Dividend Yield
- GLPG N/A
- TRN 4.29%
- EPS Growth
- GLPG N/A
- TRN N/A
- EPS
- GLPG N/A
- TRN 1.14
- Revenue
- GLPG $323,674,692.00
- TRN $2,519,800,000.00
- Revenue This Year
- GLPG $1.77
- TRN N/A
- Revenue Next Year
- GLPG $0.44
- TRN $7.24
- P/E Ratio
- GLPG N/A
- TRN $24.53
- Revenue Growth
- GLPG 5.43
- TRN N/A
- 52 Week Low
- GLPG $22.36
- TRN $22.38
- 52 Week High
- GLPG $37.78
- TRN $39.83
- Technical
- Relative Strength Index (RSI)
- GLPG 53.87
- TRN 47.17
- Support Level
- GLPG $32.37
- TRN $27.44
- Resistance Level
- GLPG $37.78
- TRN $28.40
- Average True Range (ATR)
- GLPG 0.77
- TRN 0.52
- MACD
- GLPG 0.00
- TRN -0.05
- Stochastic Oscillator
- GLPG 39.37
- TRN 20.00
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About TRN Trinity Industries Inc.
Trinity Industries Inc. sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in three main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in agriculture, construction, consumer products, energy, and chemicals.